NASDAQ:SPPI - Spectrum Pharmaceuticals Stock Price, Price Target & More

Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI."

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) issued its quarterly earnings results on Thursday, May, 3rd. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.19. The biotechnology company had revenue of $30.50 million for the quarter, compared to analysts' expectations of $25.68 million. Spectrum Pharmaceuticals had a negative return on equity of 29.47% and a negative net margin of 64.39%. The firm's revenue for the quarter was up 4.8% on a year-over-year basis. During the same period last year, the firm earned ($0.14) EPS. View Spectrum Pharmaceuticals' Earnings History.

4 analysts have issued twelve-month price objectives for Spectrum Pharmaceuticals' stock. Their forecasts range from $25.00 to $33.00. On average, they expect Spectrum Pharmaceuticals' stock price to reach $29.00 in the next twelve months. This suggests a possible upside of 22.1% from the stock's current price. View Analyst Ratings for Spectrum Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spectrum Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Spectrum Pharmaceuticals include Beigene (BGNE), Sarepta Therapeutics (SRPT), Nektar Therapeutics (NKTR), Valeant Pharmaceuticals (VRX), SAGE Therapeutics (SAGE), Alkermes (ALKS), Catalent (CTLT), Ionis Pharmaceuticals (IONS), GALAPAGOS NV/S (GLPG), United Therapeutics (UTHR), FibroGen (FGEN), Loxo Oncology (LOXO), Agios Pharmaceuticals (AGIO), Ligand Pharmaceuticals (LGND) and Dr.Reddy's Laboratories (RDY).

News articles about SPPI stock have been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. The research firm identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Spectrum Pharmaceuticals earned a news sentiment score of 0.07 on Accern's scale. They also assigned news headlines about the biotechnology company an impact score of 47.13 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Spectrum Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Fisher Asset Management LLC (0.15%), Bank of Montreal Can (0.14%), Municipal Employees Retirement System of Michigan (0.03%), Fox Run Management L.L.C. (0.02%), Ballentine Partners LLC (0.02%) and Amalgamated Bank (0.02%). Company insiders that own Spectrum Pharmaceuticals stock include Joseph W Turgeon, Kurt A Gustafson, Rajesh C Md Shrotriya, Stuart Mitchell Krassner and Thomas J Riga. View Institutional Ownership Trends for Spectrum Pharmaceuticals.

SPPI stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Bank of Montreal Can, Ballentine Partners LLC and Municipal Employees Retirement System of Michigan. Company insiders that have sold Spectrum Pharmaceuticals company stock in the last year include Joseph W Turgeon, Kurt A Gustafson, Rajesh C Md Shrotriya, Stuart Mitchell Krassner and Thomas J Riga. View Insider Buying and Selling for Spectrum Pharmaceuticals.

SPPI stock was purchased by a variety of institutional investors in the last quarter, including Hartford Investment Management Co., Fox Run Management L.L.C. and Amalgamated Bank. View Insider Buying and Selling for Spectrum Pharmaceuticals.

Shares of SPPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of SPPI stock can currently be purchased for approximately $23.75.

Spectrum Pharmaceuticals has a market capitalization of $2.47 billion and generates $128.37 million in revenue each year. The biotechnology company earns $-91,240,000.00 in net income (profit) each year or ($1.07) on an earnings per share basis. Spectrum Pharmaceuticals employs 215 workers across the globe.

Spectrum Pharmaceuticals' mailing address is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. The biotechnology company can be reached via phone at 702-835-6300 or via email at [email protected]